미분화 림프종 인산화효소(ALK) 억제제 : 대상 환자층, 경쟁 구도 및 시장 예측(2036년)

Anaplastic Lymphoma Kinase (ALK) Inhibitors Insights and Trends

• According to DelveInsight's analysis, the ALK inhibitor market size was found to be ~3,000 million in the 7MM in 2025.
• Non-small Cell Lung Cancer (NSCLC) remains the primary indication for ALK inhibitors, accounting for the majority of clinical development activity, while ALK-positive anaplastic large cell lymphoma (ALCL) represents a smaller but important therapeutic area with ongoing exploratory combination studies.
• Increasing adoption of molecular profiling, next-generation sequencing, and precision oncology approaches is improving identification of ALK-positive patients and supporting broader use of ALK-targeted therapies.
• The total incident cases of ALK inhibitors in the 7MM were ~29,500 in 2025.
• Crizotinib was the first approved ALK inhibitor for ALK-positive NSCLC and established the foundation for targeted ALK-directed therapy, although its use has gradually declined with the emergence of later-generation agents.
• Second and third-generation ALK inhibitors, such as Alectinib and Lorlatinib have significantly improved progression-free survival (PFS) and central nervous system (CNS) disease control compared with first-generation therapies in ALK-positive NSCLC.
• ALCL pipeline is limited, with most innovation coming from repurposing NSCLC ALK inhibitors rather than dedicated lymphoma programs.
• The companies involved in the emerging pipeline of ALK inhibitors include Nuvalent (Neladalkib, NVL-655), Ascentage Pharma (APG-2449), TRIANA Biomedicines (TRI-611), and others.
• Acquired resistance mutations remain a major clinical challenge, driving continued development of next-generation ALK inhibitors with broader mutation coverage and improved durability of response.

Anaplastic Lymphoma Kinase (ALK) Inhibitors Market Size and Forecast in the 7MM

• 2025 Anaplastic Lymphoma Kinase (ALK) Inhibitors Market Size: 3,000 million
• 2036 Projected Anaplastic Lymphoma Kinase (ALK) Inhibitors Market Size: 3,220 million
• Anaplastic Lymphoma Kinase (ALK) Inhibitors Growth Rate (2026-2036): 4% CAGR

DelveInsight's 'Anaplastic Lymphoma Kinase (ALK) Inhibitors - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the ALK inhibitors, historical and forecasted epidemiology, as well as the ALK inhibitors market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The ALK inhibitors market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates ALK inhibitors patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in ALK inhibitors and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Anaplastic Lymphoma Kinase (ALK) Inhibitors Market

Rising Incidence of ALK-Positive NSCLC

The increasing prevalence of NSCLC globally, along with improved diagnostic testing for ALK rearrangements, continues to expand the eligible patient population for ALK-targeted therapies. Early and accurate diagnosis supports market growth.

Growing Focus on CNS Disease Control

Brain metastases are common in ALK-positive NSCLC, increasing demand for therapies with strong intracranial efficacy. Newer ALK inhibitors demonstrating durable CNS activity are gaining significant clinical attention.

Strategic Collaborations and Research Investments

Collaborations between biotechnology and pharmaceutical companies are accelerating the development of novel ALK-targeted therapies. Increased research investment is supporting global clinical expansion and next-generation drug discovery efforts.

Anaplastic Lymphoma Kinase (ALK) Inhibitors Understanding and Treatment Algorithm

Anaplastic Lymphoma Kinase (ALK) Inhibitors Overview and Diagnosis

ALK inhibitors are targeted therapies developed to inhibit abnormal ALK signaling caused by ALK gene rearrangements, mutations, or amplifications that drive tumor growth and survival. ALK alterations are most commonly observed in a subset of NSCLC, particularly adenocarcinoma, as well as in ALCL and several rare malignancies. The introduction of ALK inhibitors has significantly transformed treatment outcomes in ALK-positive cancers by improving PFS, overall response rates, and CNS disease control compared with conventional chemotherapy. Successive generations of ALK inhibitors have been developed to overcome acquired resistance mutations and improve brain penetration.

Diagnosis of ALK-positive malignancies primarily relies on molecular and histopathological testing to identify ALK rearrangements or overexpression. In NSCLC, diagnostic approaches include fluorescence in situ hybridization, immunohistochemistry, next-generation sequencing, and reverse transcription polymerase chain reaction. Accurate molecular profiling is essential for selecting patients eligible for ALK-targeted therapies. Imaging techniques such as CT, PET, and MRI scans are also widely used for disease staging and monitoring treatment response, particularly in patients with CNS metastases, which are common in advanced ALK-positive NSCLC.

Current Anaplastic Lymphoma Kinase (ALK) Inhibitors Treatment Landscape

Treatment of ALK-positive cancers has evolved considerably with the availability of first, second, and third-generation ALK inhibitors. Currently approved therapies have demonstrated strong systemic and intracranial efficacy in NSCLC, with newer agents showing activity against resistant ALK mutations following progression on earlier therapies. In ALCL, ALK-targeted therapies are also being explored in combination regimens to improve outcomes in relapsed or refractory disease. Despite substantial therapeutic advances, acquired resistance, disease progression, and treatment-related adverse events remain major clinical challenges, driving continued development of next-generation ALK inhibitors with broader mutation coverage, improved CNS penetration, and enhanced safety profiles.

Anaplastic Lymphoma Kinase (ALK) Inhibitors Unmet Needs

The section "unmet needs of ALK inhibitors" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Acquired resistance to ALK inhibitors

2. Limited treatment options after multiple lines of therapy

3. Limited innovation in ALCL

4. Treatment-related toxicities, and others.....

Anaplastic Lymphoma Kinase (ALK) Inhibitors Total addressable market (TAM)

Key Findings from Anaplastic Lymphoma Kinase (ALK) Inhibitors Epidemiological Analysis and Forecast

• Among the 7MM, the US accounted for the highest number of total ALK cases with ~11,800 cases in 2025.
• In the US, stage-specific NSCLC incident cases were of stage IV (43%) followed by stage I (29%).
• In the US, stage-specific ALCL incident cases were of stage IV (50%) followed by stage III (23%).
• Among EU4 and the UK, Germany accounted for the highest total ALK cases, followed by France, and the least cases were accounted for by Spain in the year 2025.

Anaplastic Lymphoma Kinase (ALK) Inhibitors Drug Analysis & Competitive Landscape

The ALK inhibitors drug chapter provides a detailed, market-focused review of the emerging pipeline across Phase III-I/II clinical trials and preclinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the ALK inhibitors treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the ALK inhibitors therapeutics market.

Approved Therapies for Anaplastic Lymphoma Kinase (ALK) Inhibitors

Lorlatinib (LORBRENA) : Pfizer

Lorlatinib is a third-generation oral ALK/ROS1 tyrosine kinase inhibitor indicated for patients with ALK-positive metastatic NSCLC. It is specifically designed to overcome resistance mutations that arise with earlier ALK inhibitors and demonstrates strong penetration of the blood-brain barrier, making it highly effective in patients with CNS metastases. It is used both in first-line and previously treated settings. Recent long-term data from the Phase III (CROWN) study have reinforced its clinical value, showing durable PFS benefits and supporting its position as a leading frontline standard of care in ALK-positive NSCLC.

Alectinib (ALECENSA): Genentech and Roche

Alectinib is a highly selective, central nervous system-active, oral medicine used for the treatment of people with NSCLC whose tumours are identified as ALK-positive. Alectinib is currently approved in over 80 countries as a first-line treatment for advanced (metastatic) ALK-positive NSCLC. It is also approved in over 90 countries for the treatment of ALK-positive advanced NSCLC patients whose disease has worsened after, or who could not tolerate treatment with, crizotinib. The approval was based on the Phase III (ALINA) study showing alectinib reduced the risk of disease recurrence or death by an unprecedented 76% in people with ALK-positive early-stage resected NSCLC.

Anaplastic Lymphoma Kinase (ALK) Inhibitors Pipeline Analysis

Neladalkib (NVL-655): Nuvalent

Neladalkib is an investigational, brain-penetrant, ALK-selective inhibitor. Neladalkib is designed to remain active in tumors that have developed resistance to first, second, and third-generation ALK inhibitors, including tumors with single or compound treatment-emergent ALK mutations such as G1202R. Neladalkib has received BTD from the US FDA for the treatment of patients with locally advanced or metastatic ALK-positive NSCLC who have been previously treated with 2 or more ALK TKI and ODD for ALK-positive NSCLC.

TRI-611: TRIANA Biomedicines

TRI-611 is a novel oral, small-molecule, investigational therapy designed to target and degrade ALK fusion proteins in patients with ALK-positive NSCLC for which ALK TKIs are now the standard of care. TRI-611 is a potent, brain-penetrant molecular glue degrader that brings ALK and cereblon together through a unique binding mechanism that works independently of the kinase active site.

Anaplastic Lymphoma Kinase (ALK) Inhibitors Key Players, Market Leaders and Emerging Companies

• Pfizer
• Genentech
• Roche
• Pfizer
• Nuvalent
• TRIANA Biomedicines, and others

Anaplastic Lymphoma Kinase (ALK) Inhibitors Drug Updates

• In April 2026, Pfizer announced that it'll present new data across its diverse, industry-leading oncology pipeline and portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting. The company will share a 7-year update from the pivotal Phase III (CROWN) study that supports lorlatinib (LORBRENA) as a guideline-recommended first-line treatment for ALK-positive metastatic NSCLC.
• In April 2026, Nuvalent announced the submission of NDA for the (ALKOVE-1) study of neladalkib to the US FDA.
• In April 2026, Nuvalent announced that pivotal data for neladalkib, global (ALKOVE-1) Phase I/II clinical trial, in addition to preliminary data for ALKAZAR, will be presented during an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
• In April 2026, TRIANA Biomedicines announced that one oral and two poster presentations regarding TRI-611 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2026.
• In March 2026, Ascentage Pharma announced that four abstracts highlighting the latest preclinical results from its pipeline programs have been selected for poster presentations at the American Association of Cancer Research (AACR) Annual Meeting 2026. The data to be presented encompasses three of the Company's novel drug candidates, one of which is FAK/ALK/ROS1 tyrosine kinase inhibitor APG-2449.
• In March 2026, TRIANA Biomedicines announced that the US FDA granted Fast Track designation for TRI-611 for the treatment of ALK+ NSCLC.
• In March 2026, TRIANA Biomedicines announced that the first patient had been dosed in a Phase I/II clinical trial evaluating TRI-611 in patients with ALK-positive NSCLC.
• In January 2026, TRIANA Biomedicines announced a research collaboration with Johnson & Johnson to advance the discovery of important molecular glue targets in oncology. The collaboration aims to advance next-generation molecular glue degraders by applying TRIANA's proprietary molecular glue discovery platform to targets that have been inadequately targeted or considered undruggable.

Anaplastic Lymphoma Kinase (ALK) Inhibitors Market Outlook

The treatment landscape for ALK inhibitors in oncology has evolved significantly over the past decade, particularly in ALK-positive NSCLC, where targeted therapies have transformed patient outcomes through improved PFS and CNS penetration.

First-generation ALK inhibitor crizotinib established the foundation for targeted ALK therapy, followed by next-generation agents such as alectinib and lorlatinib, which demonstrated enhanced efficacy against resistant ALK mutations and brain metastases. Alectinib is currently a preferred frontline therapy in ALK-positive NSCLC. Additionally, it is being investigated in combination with duvelisib for relapsed or refractory ALK-positive ALCL, reflecting expanding therapeutic applications beyond lung cancer. Despite substantial clinical benefits, acquired resistance mutations and disease progression remain major challenges, underscoring the continued need for novel ALK-directed therapies with broader mutation coverage and improved tolerability.

The ALK inhibitor pipeline is steadily advancing with several emerging candidates designed to overcome resistance associated with currently approved therapies. Neladalkib (NVL-655) is a next-generation brain-penetrant ALK inhibitor specifically engineered to target diverse ALK resistance mutations while minimizing TRK-related off-target toxicities. APG-2449 is a multi-FAK/ALK/ROS1 inhibitor under clinical evaluation with potential utility in overcoming resistance mechanisms linked to tumor microenvironment signaling. TRI-611 is also being explored as a novel ALK-targeted therapeutic candidate, highlighting continued innovation within the ALK inhibitor space.

Overall, increasing adoption of precision oncology, rising molecular testing for ALK rearrangements, and the emergence of next-generation inhibitors targeting resistance mutations and CNS disease are projected to propel steady market growth across the 7MM from 2022 to 2036, yielding significant commercial opportunities for existing products and pipeline candidates.

• Among the 7MM, the US accounted for the largest market size of ALK inhibitors. i.e., USD ~1,230 million in 2025.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Anaplastic Lymphoma Kinase (ALK) Inhibitors (2022-2036 Forecast)

The ALK inhibitors market (2022-2036 forecast) is increasingly focused on next-generation targeted therapies designed to overcome resistance mutations, improve CNS penetration, and enhance long-term disease control in ALK-driven malignancies such as NSCLC and ALCL, moving beyond first-generation kinase inhibition strategies.

Crizotinib was the first approved ALK inhibitor and established the foundation for targeted therapy in ALK-positive NSCLC. However, its market position has gradually declined due to limited CNS penetration and the emergence of resistance mutations. Alectinib has gained strong market adoption as a preferred first-line therapy because of its superior CNS efficacy, longer PFS, and improved tolerability compared with crizotinib. Lorlatinib has further strengthened its competitive position by demonstrating robust activity against resistant ALK mutations and brain metastases, with long-term studies showing significant PFS benefits. Emerging next-generation candidates such as Neladalkib (NVL-655) are being developed to compete in the post-lorlatinib setting by targeting compound ALK resistance mutations while reducing off-target toxicities.

Overall, innovation in ALK inhibitors is driven by next-generation small-molecule therapies with improved selectivity, CNS penetration, and resistance mutation coverage. As these pipeline candidates advance, they are expected to expand treatment options across ALK-driven malignancies and support sustained market growth across major global markets.

Anaplastic Lymphoma Kinase (ALK) Inhibitors Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the ALK inhibitors drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

During the forecast period, approved ALK inhibitors are expected to maintain significant utilization across ALK-positive NSCLC treatment settings. Alectinib is likely to continue strong frontline adoption due to its favorable efficacy and CNS activity profile, while lorlatinib is expected to see increased uptake in resistant disease settings because of its broad resistance mutation coverage and intracranial efficacy.

Among pipeline therapies, neladalkib is expected to achieve gradual uptake as a next-generation brain-penetrant ALK inhibitor designed to target compound resistance mutations with reduced off-target toxicities. TRI-611 is expected to remain an emerging investigational candidate with uptake dependent on future clinical efficacy and safety data. Overall, future adoption of ALK inhibitors will largely depend on CNS efficacy, resistance mutation coverage, long-term tolerability, and positioning relative to established standards of care.

Detailed insights of emerging therapies' drug uptake is included in the report

Market Access and Reimbursement of Approved Therapies in Anaplastic Lymphoma Kinase (ALK) Inhibitors

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

Reimbursement is a crucial factor that affects the drug's access to the market. Often, the decision to reimburse comes down to the price of the drug relative to the benefit it produces in treated patients. To reduce the healthcare burden of these high-cost therapies, many payment models are being considered by payers and other industry insiders.

NOTE: Further Details are provided in the final report....

Anaplastic Lymphoma Kinase (ALK) Inhibitors Therapies Price Scenario & Trends

Pricing and analogue assessment of ALK inhibitors therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market ALK inhibitorsess, adherence, and long-term uptake.

Industry Experts and Physician Views for Anaplastic Lymphoma Kinase (ALK) Inhibitors

To keep up with ALK inhibitors market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the Anaplastic Lymphoma Kinase (ALK) Inhibitors emerging therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in ALK inhibitors, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 15+ KOLs to gather insights at the country level. Centers such as the Duke Molecular Physiology Institute, Department of Nephrology, Hospital Universitario Fundacion Alcorcon, and Nippon Medical School, etc. were contacted. Their opinion helps understand and validate current and emerging ALK inhibitors therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in ALK inhibitors.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis.

In the SWOT analysis of ALK inhibitors, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of ALK inhibitors, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborative profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the ALK inhibitors market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM ALK inhibitors market.

Report Insights

• Anaplastic Lymphoma Kinase (ALK) Inhibitors Patient Population Forecast
• Anaplastic Lymphoma Kinase (ALK) Inhibitors Therapeutics Market Size
• Anaplastic Lymphoma Kinase (ALK) Inhibitors Pipeline Analysis
• Anaplastic Lymphoma Kinase (ALK) Inhibitors Market Size and Trends
• Anaplastic Lymphoma Kinase (ALK) Inhibitors Market Opportunity (Current and forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Anaplastic Lymphoma Kinase (ALK) Inhibitors Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Anaplastic Lymphoma Kinase (ALK) Inhibitors Treatment Addressable Market (TAM)
• Anaplastic Lymphoma Kinase (ALK) Inhibitors Competitive Landscape
• Anaplastic Lymphoma Kinase (ALK) Inhibitors Major Companies Insights
• Anaplastic Lymphoma Kinase (ALK) Inhibitors Price Trends and Analogue Assessment
• Anaplastic Lymphoma Kinase (ALK) Inhibitors Therapies Drug Adoption/Uptake
• Anaplastic Lymphoma Kinase (ALK) Inhibitors Therapies Peak Patient Share Analysis

Report Assessment

• Anaplastic Lymphoma Kinase (ALK) Inhibitors Current Treatment Practices
• Anaplastic Lymphoma Kinase (ALK) Inhibitors Unmet Needs
• Anaplastic Lymphoma Kinase (ALK) Inhibitors Clinical Development Analysis
• Anaplastic Lymphoma Kinase (ALK) Inhibitors Emerging Drugs Product Profiles
• Anaplastic Lymphoma Kinase (ALK) Inhibitors Market attractiveness
• Anaplastic Lymphoma Kinase (ALK) Inhibitors Qualitative Analysis (SWOT and conjoint analysis)

FAQs:

Market Insights

• What was the ALK inhibitors market size, the market size by therapies, market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of ALK inhibitors?
• What are the disease risks, burdens, and unmet needs of ALK inhibitors? What will be the growth opportunities across the 7MM concerning the patient population with ALK inhibitors?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of ALK inhibitors? What are the current guidelines for treating ALK inhibitors in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the ALK inhibitors market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarize and simplify complex datasets with in the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary

4. Key Events

• 4.1. Upcoming Key Catalyst
• 4.2. Key Conferences And Meetings
• 4.3. Key Transactions And Collaborations
• 4.4. News Flow

5. Epidemiology and Market Methodology of Anaplastic Lymphoma Kinase (ALK) Inhibitors

6. Anaplastic Lymphoma Kinase (ALK) Inhibitors Market Overview at a Glance

• 6.1. Emerging Landscape Analysis (By Molecule Type, Phase, and Route of Administration [ROA])
• 6.2. Market Share of Anaplastic Lymphoma Kinase (ALK) Inhibitors By Therapies (%) in the 7MM in 2025
• 6.3. Market Share of Anaplastic Lymphoma Kinase (ALK) Inhibitors By Therapies (%) in the 7MM in 2036

7. Anaplastic Lymphoma Kinase (ALK) Inhibitors Disease Background And Overview

• 7.1. Introduction
• 7.2. Target Indications
• 7.3. Treatment and Management
  • 7.3.1. Treatment Algorithm

8. Epidemiology and Patient Population of Anaplastic Lymphoma Kinase (ALK) Inhibitors

• 8.1. Key Findings
• 8.2. Assumption and Rationale
• 8.3. Total Cases of Selected Indication for Anaplastic Lymphoma Kinase (ALK) Inhibitors in the 7MM
• 8.4. Total Eligible Patient Pool for Anaplastic Lymphoma Kinase (ALK) Inhibitors in the 7MM
• 8.5. Total Treated Cases in Selected Indications Anaplastic Lymphoma Kinase (ALK) Inhibitors in the 7MM

9. Marketed Therapies

• 9.1. Marketed Competitive Landscape of Anaplastic Lymphoma Kinase (ALK) Inhibitors
• 9.2. Lorlatinib (LORBRENA): Pfizer
  • 9.2.1. Product Description
  • 9.2.2. Regulatory Milestones
  • 9.2.3. Other Developmental Activities
  • 9.2.4. Summary of Pivotal Trials
  • 9.2.5. Analyst Views
• 9.3. Alectinib (ALECENSA): Genentech and Roche
  • 9.3.1. Product Description
  • 9.3.2. Regulatory Milestones
  • 9.3.3. Other Developmental Activities
  • 9.3.4. Summary of Pivotal Trials
  • 9.3.5. Analyst Views

10. Emerging Therapies

• 10.1. Emerging Competitive Landscape of Anaplastic Lymphoma Kinase (ALK) Inhibitors
• 10.2. Neladalkib (NVL-655): Nuvalent
  • 10.2.1. Product Description
  • 10.2.2. Other Developmental Activities
  • 10.2.3. Clinical Development
    • 10.2.3.1. Clinical Trial Information
  • 10.2.4. Safety and Efficacy
  • 10.2.5. Analyst Views
• 10.3. APG-2449: Ascentage Pharma
  • 10.3.1. Product Description
  • 10.3.2. Other Developmental Activities
  • 10.3.3. Clinical Development
    • 10.3.3.1. Clinical Trial Information
  • 10.3.4. Safety and Efficacy
  • 10.3.5. Analyst Views

11. Anaplastic Lymphoma Kinase (ALK) Inhibitors: Seven Major Market Analysis

• 11.1. Key Findings
• 11.2. Market Outlook of Anaplastic Lymphoma Kinase (ALK) Inhibitors
• 11.3. Conjoint Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors
• 11.4. Key Market Forecast Assumptions
  • 11.4.1. Cost Assumptions
  • 11.4.2. Pricing Trends
  • 11.4.3. Analogue Assessment
  • 11.4.4. Launch Year and Therapy Uptakes
• 11.5. Total Market Size of Anaplastic Lymphoma Kinase (ALK) Inhibitors in the 7MM
• 11.6. The United States
  • 11.6.1. Total Market Size of Anaplastic Lymphoma Kinase (ALK) Inhibitors in the United States
  • 11.6.2. Market Size of Anaplastic Lymphoma Kinase (ALK) Inhibitors by Therapies in the United States
• 11.7. EU4 and the UK
  • 11.7.1. Total Market Size of Anaplastic Lymphoma Kinase (ALK) Inhibitors in EU4 and the UK
  • 11.7.2. Market Size of Anaplastic Lymphoma Kinase (ALK) Inhibitors by Therapies in EU4 and the UK
• 11.8. Japan
  • 11.8.1. Total Market Size of Anaplastic Lymphoma Kinase (ALK) Inhibitors in Japan
  • 11.8.2. Market Size of Anaplastic Lymphoma Kinase (ALK) Inhibitors by Therapies in Japan

12. Unmet Needs of Anaplastic Lymphoma Kinase (ALK) Inhibitors

13. SWOT Analysis of Anaplastic Lymphoma Kinase (ALK) Inhibitors

14. KOL Views of Anaplastic Lymphoma Kinase (ALK) Inhibitors

• 14.1. Expert/KOL Interview Highlights

15. Market Access and Reimbursement of Anaplastic Lymphoma Kinase (ALK) Inhibitors

• 15.1. The US
• 15.2. In EU4 and the UK
  • 15.2.1. Germany
  • 15.2.2. France
  • 15.2.3. Italy
  • 15.2.4. Spain
  • 15.2.5. United Kingdom
• 15.3. Japan
• 15.4. Summary and Comparison of Market accesess and Pricing Policy Developments in 2025
• 15.5. Market Accesess and Reimbursement of Anaplastic Lymphoma Kinase (ALK) Inhibitors

16. Appendix

• 16.1. Bibliography
• 16.2. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight